SCHEMBL25822689

SCHEMBL25822689

CN1CCCN(c2ccc(Nc3nc4ccc(-c5cn[nH]c5)cc4n4ccnc34)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 5/20 0.51
STK17A Q9UEE5 1/20 0.43
SYK P43405 7/20 0.43
ROCK2 O75116 1/20 0.41
MAP4K1 Q92918 2/20 0.41
EGFR P00533 1/20 0.41
MAPKAPK2 P49137 3/20 0.40
JAK2 O60674 1/20 0.40
NTRK1 P04629 1/20 0.40
ROS1 P08922 1/20 0.40
CSNK2A2 P19784 1/20 0.40
FLT3 P36888 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40
BTK Q06187 1/20 0.40
PTK6 Q13882 1/20 0.40
CSNK2A3 Q8NEV1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25822683 0.97 MAPKAPK5 (0.54) MAPKAPK5STK17ASYKMAP4K1EGFR
SCHEMBL25822675 0.88 MAPKAPK5 (0.67) MAPKAPK5SYKJAK2NTRK1ROS1
SCHEMBL25822739 0.87 MAPKAPK5 (0.49) MAPKAPK5STK17AMAP4K1EGFRMAPKAPK2
SCHEMBL25822687 0.86 SYK (0.54) MAPKAPK5SYKJAK2NTRK1ROS1
SCHEMBL25822692 0.85 MAPKAPK5 (0.51) MAPKAPK5SYKJAK2NTRK1ROS1
SCHEMBL25822696 0.85 MAPKAPK5 (0.56) MAPKAPK5SYKJAK2NTRK1ROS1
SCHEMBL25822684 0.84 SYK (0.57) MAPKAPK5SYKJAK2
SCHEMBL21848344 0.83 ROCK2 (0.44) MAPKAPK5STK17AROCK2MAP4K1EGFR
SCHEMBL25823408 0.83 ALK (0.38) MAPKAPK5STK17AROCK2MAP4K1
SCHEMBL25822740 0.83 MAPKAPK5 (0.51) MAPKAPK5STK17AEGFRMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) 2023-07-13 US disclosed
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 OCUMENSION THERAPEUTICS (SUZHOU) CO., LTD. (CN) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219960-A1 1H-PYRAZOLE DERIVATIVE AND APPLICATION THEREOF AS DUAL TARGET INHIBITOR OF SYK AND VEGFR2 SYK, KDR, FLT1 MAPKAPK5 216/4885STK17A 90/4885SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.